Il Dong Pharmaceutical Co Ltd

Il Dong Pharmaceutical maintains a market price of 21,200 KRW per share, with a market capitalization of 667.97 billion KRW. The company's price-to-earnings ratio is 24.15, and its price-to-book ratio is 2.71, indicating a premium valuation relative to its book value. The enterprise value to EBITDA ratio is 41.23, suggesting a high valuation multiple compared to its earnings before interest, taxes, depreciation, and amortization. The company's profitability is reflected in its return on equity of 11.23% and return on assets of 4.83%. These figures are below the typical thresholds for high-performing pharmaceutical firms, indicating that the company is generating returns, but not at a level that would be considered exceptional within the industry. The operating margin, calculated as operating income of 18.28 billion KRW on revenue of 566.93 billion KRW, is 3.22%, which is in line with the industry median. Geographically, Il Dong Pharmaceutical's revenue is concentrated in South Korea, with no significant international operations disclosed. The company's business is primarily driven by its domestic pharmaceutical products, and there is no indication of diversification into other regions or therapeutic areas. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. The current fiscal year's revenue is 566.93 billion KRW, and the outlook for the next fiscal year is not expected to deviate significantly from this figure. The company's capital expenditure is negative, indicating a reduction in investment in physical assets, which may suggest a focus on cost optimization or a shift in strategic priorities. The company's liquidity position is characterized as medium risk, with a current ratio of 0.96, indicating that its current liabilities exceed its current assets. The debt-to-equity ratio is 0.61, suggesting a moderate level of leverage. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk if not managed effectively. Recent events and disclosures do not indicate any significant changes in the company's operations or financial strategy. The company's recent filings and transcripts do not highlight any new product launches, strategic partnerships, or major regulatory developments that would significantly impact its business outlook.